The association of glucagon with disease severity and progression in patients with autosomal dominant polycystic kidney disease: an observational cohort study

BACKGROUND: Mammalian target of rapamycin (mTOR) inhibitors and ketogenesis have been shown to ameliorate disease progression in experimental autosomal dominant polycystic kidney disease (ADPKD). Glucagon is known to lower mTOR activity and stimulate ketogenesis. We hypothesized that in ADPKD patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Knol, Martine G E, Kramers, Bart J, Gansevoort, Ron T, van Gastel, Maatje D A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8690142/
https://www.ncbi.nlm.nih.gov/pubmed/34950469
http://dx.doi.org/10.1093/ckj/sfab112

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8690142/
https://www.ncbi.nlm.nih.gov/pubmed/34950469
http://dx.doi.org/10.1093/ckj/sfab112

Ejemplares similares